Spots Global Cancer Trial Database for Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Official Title: A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies
Study ID: NCT05411133
Interventions
Study Description
Brief Summary: This study aims to find out: 1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. 2. To find out how study drug is broken down in the body 3. To know the effects of the study drug on the tumor.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southern Oncology Clinical Research Unit, Adelaide, , Australia
St George Private Hospital, Sydney, , Australia
Queen Mary Hospital, Hong Kong, , Hong Kong
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
